Cargando…

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

The disposition of 5-fluorouracil (FUra) was studied in 19 colorectal cancer patients during treatment with FUra and high-dose leucovorin (LV) with or without interferon alpha 2a (IFN-alpha). All received LV 200 mg m-2 over 2 h, then FUra 400 mg m-2 over 5 min then FUra 400 mg m-2 over 22 h, repeate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seymour, M. T., Patel, N., Johnston, A., Joel, S. P., Slevin, M. L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033410/ https://www.ncbi.nlm.nih.gov/pubmed/7917928

Ejemplares similares

Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
por: Seymour, M. T., et al.
Publicado: (1994)

The effects of 5-fluorouracil and interferon-alpha on early healing of experimental intestinal anastomoses.
por: de Waard, J. W., et al.
Publicado: (1996)

The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
por: Nichols, P. H., et al.
Publicado: (1994)

Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.
por: Ferguson, J. E., et al.
Publicado: (1995)

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
Publicado: (2001)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
por: Cascinu, S., et al.
Publicado: (1994)

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.
por: Piga, A., et al.
Publicado: (1996)

A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.
por: Johnson, P. W., et al.
Publicado: (1991)

Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
por: Marín-Lopez, Alejandro, et al.
Publicado: (2019)

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
por: Goey, S. H., et al.
Publicado: (1996)

Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors
Publicado: (1995)

Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha
por: Rycroft, Daniel, et al.
Publicado: (2015)

Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha.
por: Louvet, C., et al.
Publicado: (1996)

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
por: Bernhard, H., et al.
Publicado: (1995)

Fluorouracil/oxaliplatin/panitumumab: Lack of efficacy: case report
Publicado: (2022)

Oral Pharmacokinetics of a Chitosan-Based Nano- Drug Delivery System of Interferon Alpha
por: Imperiale, Julieta C., et al.
Publicado: (2019)

Correction: Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha
Publicado: (2015)

Pharmacokinetic characteristics and anticancer effects of 5-Fluorouracil loaded nanoparticles
por: Li, Su, et al.
Publicado: (2008)

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
por: Braybrooke, J P, et al.
Publicado: (2000)

Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics
por: Hsieh, Chen-Hsi, et al.
Publicado: (2010)

Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma
por: Okada, Youhei, et al.
Publicado: (2018)

Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.
por: McDermott, B. J., et al.
Publicado: (1983)

Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil—Radiotherapy–Pharmacokinetics Phenomenon
por: Liu, Ju-Han, et al.
Publicado: (2020)

Effect of Ketorolac on Pharmacokinetics and Pharmacodynamics of 5-Fluorouracil: In Vivo and In Vitro Study
por: Atefinezhad, Motahare, et al.
Publicado: (2022)

Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells
por: Wada, Hiroshi, et al.
Publicado: (2009)

Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil
por: Schmulenson, Eduard, et al.
Publicado: (2022)

Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases
por: Kobawala, Toral P., et al.
Publicado: (2011)

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial
por: Ravaud, A, et al.
Publicado: (2003)

Galectin-9 and Interferon-Gamma Are Released by Natural Killer Cells upon Activation with Interferon-Alpha and Orchestrate the Suppression of Hepatitis C Virus Infection
por: Carreca, Anna Paola, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study
por: García-García, Idrian, et al.
Publicado: (2010)

Pharmacokinetic Modulation of Plasma 5‐Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5‐Fluorouracil
por: Fujii, Setsuro, et al.
Publicado: (1989)

A Novel Class of Antitumor Prodrug, 1‐(2′‐Oxopropyl)‐5‐fluorouracil (OFU001), That Releases 5‐Fluorouracil upon Hypoxic Irradiation
por: Shibamoto, Yuta, et al.
Publicado: (2000)

Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin
por: Hsieh, Chen-Hsi, et al.
Publicado: (2013)

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma
por: Daryani, VM, et al.
Publicado: (2016)

Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report
por: Morita, Tatsuo, et al.
Publicado: (2009)

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.
por: Boublil, J. L., et al.
Publicado: (1985)

A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
por: Cheeseman, S L, et al.
Publicado: (2002)

Differential effect of interferon-alpha treatment on AEA and 2-AG levels
por: Zajkowska, Zuzanna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ve5s12hf841ghhru6dt2jef991